文献速递血液净化与透析

血液透析 Medicare 患者衰弱的边际成本

The Marginal Cost of Frailty Among Medicare Patients on Hemodialysis.
PubMed 文献 · Kidney Int Rep · 2019-12-06

本研究基于 ACTIVE/ADIPOSE 队列中 425 例成人血液透析患者,回顾性分析衰弱的边际成本。结果显示,衰弱患者年均费用较非衰弱者高 22%,差异主要由住院支出驱动;研究期间死亡者中该差异更显著。

要点

  • 衰弱血液透析患者年均费用较非衰弱者高 22%。
  • 费用差异主要由住院支出增加驱动。
  • 研究期间死亡者中衰弱相关费用差异更显著。

核心结论

  • 衰弱透析患者费用显著高于非衰弱者,主要由住院费用驱动,临终前费用更高。

研究设计与样本

  • 回顾性队列分析,纳入 ACTIVE/ADIPOSE 研究中 425 例以 Medicare 为主要支付方的成人血液透析患者。

主要发现

  • 衰弱者年均费用为 87,600 美元(95%CI 76,800-100,000),非衰弱者为 71,800 美元(95%CI 64,800-79,600)。
  • 衰弱者费用较非衰弱者高 22%(95%CI 9.6%-35.8%)。
  • 费用差异主要由住院支出更高驱动,且在研究期间死亡者中更明显。

临床怎么用

  • 对血液透析患者进行衰弱评估可能有助于识别高费用风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dialysis patients incur disproportionately high costs compared with other Medicare beneficiaries. Care for frail individuals may be even more costly. We examined the extent to which frailty contributes to higher costs among dialysis patients. METHODS: We used ACTIVE/ADIPOSE (A Cohort to Investigate the Value of Exercise/Analyses Designed to Investigate the Paradox of Obesity and Survival in ESRD) enrollees (adult hemodialysis patients evaluated from June 2009 to August 2011) in a retrospective cohort analysis. Individuals using Medicare as the primary payer were included. Fried's frailty phenotype was evaluated at baseline, 12, and 24 months. Costs were derived from linkage with the US Renal Data System (USRDS) and Medicare claims data. We used generalized estimating equations (GEEs) incorporating time-updated frailty and costs to evaluate adjusted point estimates and the marginal cost associated with being frail. We also investigated if frail patients who died during the study incurred higher costs than those who survived. RESULTS: Among 771 enrollees in ACTIVE/ADIPOSE, 425 met inclusion criteria. Mean age was 56 ± 13 years, body mass index (BMI) 29.2 ± 7.1 kg/m2, 42.4% were women, and 29.0% were frail at baseline. Over a mean follow-up of 2.3 years, frail individuals incurred 22% (95% confidence interval [CI] 9.6%-35.8%) higher costs compared with nonfrail individuals ($87,600 per patient per year [pppy], 95% CI 76,800-100,000, vs. $71,800 pppy, 95% CI 64,800-79,600), the difference was driven primarily by higher inpatient expenditures. The difference between frail and nonfrail patients' inpatient expenditures was even more pronounced among those who died during the study compared with those who survived. CONCLUSIONS: Frail dialysis patients incur a significantly higher cost relative to their nonfrail counterparts, primarily driven by higher inpatient costs. Frail patients near end of life incur even higher costs.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sy J, Streja E, Grimes B, et al. The Marginal Cost of Frailty Among Medicare Patients on Hemodialysis. Kidney Int Rep. 2019. PMID: 32154450. doi:10.1016/j.ekir.2019.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。